Avive Hires Eric Lang as VP of Operations

SAN FRANCISCO, CA – (December 13, 2018) – Avive Solutions, Inc., a leading developer of a next-generation Automated External Defibrillator (AED) addressing the global public health issue of Sudden Cardiac Arrest (“SCA”), today announced that Eric Lang has joined the Company as its Vice President of Operations.

Eric has over 20 years of experience in operations leadership roles developing Class II and Class III medical devices and combination products.

He has worked at Fortune 500 and startup companies that designed, manufactured, and sold devices for cardiology, hemodialysis, OB/GYN, intensive care therapy, and most recently worked on a critical care monitoring diagnostic tool for predictive health.

Most notably, Eric has served as the Director of Manufacturing Operations at XTENT (NYSE: XTNT), the Director of Manufacturing Engineering at Evalve (acq. by Abbott), and most recently the Director of Manufacturing at Potrero Medical.

“Eric has deep experience in leading manufacturing operations and quality for early-stage medical device companies and has displayed a strong track record of success,” said Rory Beyer, CEO of Avive. “We are excited that Eric has joined the team at this important time in the Company’s growth as we continue to progress toward commercialization.”

“It is exciting to join a team-leading innovation to transform the Automated External Defibrillator industry, which will increase access to these life-saving devices and create an unparalleled impact in the process,” said Eric Lang, Vice President of Operations of Avive. “I am eager to embrace this exciting challenge to apply novel technologies and business models to achieve a new level of success in health care, and deliver to the patient a superior product and value than what is currently available.”

About Avive Solutions, Inc.

Avive Solutions, Inc is a San Francisco-based privately-held healthcare technology company developing a next-generation automated external defibrillator and software solutions in an effort to significantly increase survival rates from Sudden Cardiac Arrest.